Global Option and Evaluation Partnership Terms and Agreements in Pharma, Experiments, Research, Analysis, Evolutions, 2014-2019

Posted on 2019-04-03 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Apr-03 — /EPR Network/ —The global market status for Option and Evaluation is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Option and Evaluation” Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019, which tends to deliver in-depth knowledge associated to the Option and Evaluation market for the present and forecasted period until 2019. Furthermore, the report examines the target market based on market size, revenue and geography; making it quite useful for the readers.

Get Sample Copy of This Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2222644

The Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report.

This report provides details of the latest option and evaluation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of option and evaluation agreements from 2014 to 2019.

There are two major forms of deal term that allow a party to a deal to secure rights to an asset subject to a future event namely, option and evaluation.

Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to a period of time to evaluate the quality, scope and applicability of the technology to its intended endpoint.Normally the technology is at an early stage and/or unproven and the partnering companywishes to assess the technology as part of the due diligence process in advance of signing a long term licensing agreement.

Evaluation agreements have been a mainstay of technology licensing from the earliest days.

An option agreement differs in that the option is often an integral part of an agreement already entered by the parties, providing the party with the option right to retain or extend certain rights to the technology already partnered.

Option agreements are becoming increasingly popular as they create additional flexibility within a deal for additional rights that the parties do notwish to commit at the outset of the agreement.

This report focuses on option and evaluation agreements and clauses within broader agreements between big pharma-big pharma, big pharma smaller company, and smaller company-smaller company, providing a detailed insight into all such deals.

The report provides a detailed understanding and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor retains either a option and evaluation right to the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to advance the product or compound to a point where the licensee might seek to proceed to a licensing deal.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all option and evaluation deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies to enable understanding of both pure option and evaluation deals and multicomponent deals where option and evaluation forms a part.

Chapter 4 provides a review of the leading option and evaluation deals since 2014. Deals are listed by headline value, signed by big pharma and big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of option and evaluation deals signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

In addition the report includes a series of appendices containing a comprehensive listing of all option and evaluation deals announced since 2014.

Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

BROWSE Full Report NOW @ https://www.marketresearchhub.com/report/global-option-and-evaluation-partnership-terms-and-agreements-in-pharma-biotech-and-diagnostics-2014-2019-report.html

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in option and evaluation dealmaking

2.1. Introduction
2.2. Difference between option and evaluation deals
2.2.1. Types of option agreement
2.3. Trends in option and evaluation deals since 2014
2.3.1. Option and evaluation dealmaking by year since 2014
2.3.2. Option and evaluation dealmaking by phase of development since 2014
2.3.3. Option and evaluation dealmaking by industry sector since 2014
2.3.4. Option and evaluation dealmaking by therapy area since 2014
2.3.5. Option and evaluation dealmaking by technology type since 2014
2.3.6. Option and evaluation dealmaking by most active company since 2014
2.4. Option-based deals
2.4.1. Attributes of option-based deals
2.4.2. Reasons for entering an option-based deal
2.4.3. Uptake of option exercise
2.4.4.The future of option-based deals
2.5. Co-promotion options
2.5.1. Attributes of co-promotion in multi-component deals
2.5.2. Reasons for including co-promotion options in a deal
2.5.3. Uptake of co-promotion rights
2.5.4. Co-promotion rights as bargaining chips
2.5.5. The future of co-promotion as part of multicomponent deals
2.6. Company acquisition options
2.6.1. Case study 1: Cephalon Ception
2.6.2. Case study 2: Endo Indevus
2.6.3. The future of option to acquire deals

Chapter 3 Overview of option and evaluation deal structure

3.1. Introduction
3.2. Option and evaluation agreement structure
3.2. Example evaluation agreements
3.2.1.a. Case study 3: Idenix Pharmaceuticals Janssen Pharmaceuticals
3.3. Option agreement structure
3.3.1. Example option agreements
3.3.1.a. Option to license
Case study 4: Biogen Idec Isis Pharmaceuticals
3.3.1.b. Option to extend/expand applications/territories
Case study 5: Novartis Prometheus
3.3.1.c. Option to finance
Case study 6: Amarantus BioSciences Power3 Medical Products
3.3.1.d. Option to co-promote
Case study 7: Teva OncoGenex Pharmaceuticals
3.3.1.e. Option to manufacture/supply
Case study 8: NPS Allelix Nycomed
3.4. Option to acquire agreement structure
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 9: ViroPharma Meritage Pharma
3.4.1.b. Case study 10: Nuvasive Progentix Orthobiology

More Information………@@@

Enquire about this Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2222644

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick